Literature DB >> 308999

Limited effect of erythrocyte and plasma infusions in adenosine deaminase deficiency.

F C Schmalstieg, G C Mills, J A Nelson, L T May, A S Goldman, R M Goldblum.   

Abstract

A 10-month-old child with a profound deficiency of adenosine deaminase and severe combined immunodeficiency was treated for a period of 17 months with red cell and plasma transfusions containing normal amounts of the deficient enzyme. Following each transfusion, the plasma adenosine, red cell and lymphocyte ATP, urinary adenine, and urinary deoxyadenosine decreased transiently. During this period, the absolute blood lymphocyte count rose and a limited increased in the response of the lymphocytes to PHA-P was observed. Delayed hypersensitivity skin tests remained negative during the transfusion periods. A quantitative elevation of serum immunoglobulins occurred, but specific antibody formation was not elicited. In contrast to a previous report of successful therapy of ADA deficiency with red cell and plasma infusions, this patient responded poorly to enzyme replacement therapy. The difference may be related to a more profound enzyme deficiency in our patient.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308999     DOI: 10.1016/s0022-3476(78)80894-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Effect of red cell transfusions, thymic hormone and deoxycytidine in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  E G Davies; R J Levinsky; D R Webster; H A Simmonds; D Perrett
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

3.  Prenatal diagnosis for adenosine deaminase deficiency.

Authors:  J B Ziegler; M B Van der Weyden; C H Lee; A Daniel
Journal:  J Med Genet       Date:  1981-04       Impact factor: 6.318

4.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

5.  Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child.

Authors:  R Hirschhorn; V Roegner; A Rubinstein; P Papageorgiou
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

6.  Severe combined immunodeficiency and adenosine deaminase deficiency: failure of enzyme replacement therapy.

Authors:  J B Ziegler; C H Lee; M B Van der Weyden; A S Bagnara; J Beveridge
Journal:  Arch Dis Child       Date:  1980-06       Impact factor: 3.791

7.  Substrate inhibition of adenosine phosphorylation in adenosine deaminase deficiency and adenosine-mediated inhibition of PP-ribose-P dependent nucleotide synthesis in hypoxanthine phosphoribosyltransferase deficient erythrocytes.

Authors:  F F Snyder; C Dyer; J E Seegmiller; R M Goldblum; G C Mills; F C Schmalstieg
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.